|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500103723 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-04 17:30:00 |
|
注册时间: Date of Registration: |
2025-06-04 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
恒格列净对 2 型糖尿病患者血尿酸的影响作用:一项真实世界研究 |
|
Public title: |
The effect of Ertugliflozin on blood uric acid in patients with type 2 diabetes: A real-world study. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
恒格列净对 2 型糖尿病患者血尿酸的影响作用:一项真实世界研究 |
|
Scientific title: |
The effect of Ertugliflozin on blood uric acid in patients with type 2 diabetes: A real-world study. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
徐积兄 |
研究负责人: |
徐积兄 |
|
Applicant: |
Jixiong Xu |
Study leader: |
Jixiong Xu |
|
申请注册联系人电话: Applicant telephone: |
+86 133 0708 6069 |
研究负责人电话:
Study leader's |
+86 791 8869 1867 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Jixiong.Xu@ncu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
xujixiong@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江西省南昌市东湖区永外正街17号 |
研究负责人通讯地址: |
南昌市东湖区永外正街17号 |
|
Applicant address: |
No. 17, Yongwai Zhengjie, Donghu District, Nanchang City, Jiangxi Province |
Study leader's address: |
17# Yongwai Zhengjie, Nanchang City, Jiangxi Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南昌大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Nanchang University |
||
|
研究负责人所在单位: |
南昌大学第一附属医院 |
||
|
Affiliation of the Leader: |
The first affiliated hostipal of nanchang university |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IT[2023]临伦审第356号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南昌大学第一附属医院IIT项目伦理审查委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Affiliated Hospital of Nanchang University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-05 00:00:00 | ||
|
伦理委员会联系人: |
舒展 |
||
|
Contact Name of the ethic committee: |
Shu Zhan |
||
|
伦理委员会联系地址: |
南昌市东湖区永外正街17号 |
||
|
Contact Address of the ethic committee: |
17# Yongwai Zhengjie, Nanchang City, Jiangxi Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 791 8869 2201 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
493831410@qq.com |
|
研究实施负责(组长)单位: |
南昌大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The first affiliated hostipal of nanchang university |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
南昌市东湖区永外正街17号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
17# Yongwai Zhengjie, Nanchang City, Jiangxi Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Jiangsu Hengrui Medicine Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
2型糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Type 2 diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
评价应用恒格列净在真实世界中对 2 型糖尿病患者血尿酸水平的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of henagliflozin application on the serum uric acid level of patients with type 2 diabetes in the real world |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.回顾性纳入标准:; (1).符合世界卫生组织(WHO)关于 2 型糖尿病的诊断标准; (2).性别不限;年龄>=18 岁; (3).已接受恒格列净降糖治疗(>=6 个月); (4).接受恒格列净治疗前 1 个月内至少进行 1 次血尿酸测量,服用恒格列净后第 5~7 个月至少进行 1 次血尿酸测量; 2.前瞻性纳入标准:; (1).符合世界卫生组织(WHO)关于 2 型糖尿病的诊断标准; (2).性别不限;年龄>=18岁; (3).患者开始接受恒格列净降糖治疗; (4). 6个月内未接受其他SGLT2i; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Retrospective Inclusion Criteria:; 1). Patients who meet the World Health Organization (WHO) diagnostic criteria for type 2 diabetes; 2). No gender restrictions; age >=18 years; 3). Have received henagliflozin treatment for blood sugar control (>=6 months); 4). At least one blood uric acid measurement within one month before starting henagliflozin treatment; and at least one blood uric acid measurement between the 5th and 7th month of henagliflozin treatment. 2. Prospective Inclusion Criteria:; 1). Patients who meet the World Health Organization (WHO) diagnostic criteria for type 2 diabetes; 2). No gender restrictions; age >=18 years; 3). Patients beginning henagliflozin treatment for blood sugar control; 4). Have not received any other SGLT2 inhibitors within the past 6 months. |
||||||||||||||||||||||
|
排除标准: |
1.回顾性排除标准:; 1). 由于其他疾病所致高血糖状态; 2). 1 型糖尿病; 3). 6 个月内出现严重的糖尿病并发症,如糖尿病酮 症酸中毒、高渗性高血糖综合征或乳酸酸中毒; 4). 对钠葡萄糖转运蛋白 2 抑制剂(SGLT2i)药物过敏; 5). 严重肝肾功能受损(肾小球滤过率[eGFR]<30 mL/min/1.73m2;天冬氨酸氨基转移酶 [AST] 、丙氨酸氨 基转移酶[ALT] 或碱性磷酸酶水平高于正常上限三倍); 6). 入组前 6 个月内及随访期间已接受降尿酸药物 4 (包括别嘌呤醇、非布索坦、苯溴马隆和尿酸酶)治疗的患者; 7). 恶性肿瘤及其他严重疾病; 8). 孕妇或哺乳期妇女; 9). 临床资料不完整的患者; 2. 前瞻性排除标准:; 1. 由于其他疾病所致高血糖状态; 2. 1 型糖尿病; 3. 6个月内出现严重的糖尿病并发症,如糖尿病酮症酸中毒、高渗性高血糖综合征或乳酸酸中毒; 4. 对SGLT2i药物过敏; 5. 严重肝肾功能受损(肾小球滤过率[eGFR]<30 mL/min/1.73m2;天冬氨酸氨基转移酶 [AST] 、丙氨酸氨基转移酶[ALT] 或碱性磷酸酶水平高于正常上限三倍); 6. 6个月内已接受降尿酸药物(包括别嘌呤醇、非布索坦和苯溴马隆)治疗的患者; 7. 恶性肿瘤及其他严重疾病; 8. 孕妇或哺乳期妇女; 9. 临床资料不完整的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Retrospective Exclusion Criteria:; 1. Hyperglycemia due to other diseases; 3. Type 1 diabetes; 3. Severe diabetic complications within the past 6 months, such as diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome, or lactic acidosis; 4. Allergy to sodium-glucose cotransporter 2 inhibitors (SGLT2i); 5. Severe liver or kidney impairment (glomerular filtration rate [eGFR] <30 mL/min/1.73m2; aspartate aminotransferase [AST], alanine aminotransferase [ALT], or alkaline phosphatase levels more than three times the upper limit of normal); 6. Patients who have received uric acid-lowering drugs (including allopurinol, febuxostat, and benzbromarone) within the past 6 months or during the follow-up period; 7. Malignant tumors and other serious diseases; 8. Pregnant or lactating women; 9. Patients with incomplete clinical data. 2. Prospective Exclusion Criteria:; 1. Hyperglycemia due to other diseases; 2. Type 1 diabetes; 3. Severe diabetic complications within the past 6 months, such as diabetic ketoacidosis, hyperosmolar hyperglycemic syndrome, or lactic acidosis; 4. Allergy to SGLT2i; 5. Severe liver or kidney impairment (glomerular filtration rate [eGFR] <30 mL/min/1.73m2; aspartate aminotransferase [AST], alanine aminotransferase [ALT], or alkaline phosphatase levels more than three times the upper limit of normal); 6. Patients who have received uric acid-lowering drugs (including allopurinol, febuxostat, and benzbromarone) within the past 6 months; 7. Malignant tumors and other serious diseases; 8. Pregnant or lactating women; 9. Patients with incomplete clinical data. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-30 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-30 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据于2024年5月1日开始录入EDC数据管理系统中,数据录入网站为https://medical.jianfancloud.com/#/login |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data to begin on May 1, 2024 entry in the EDC data management system, data entry for https://medical.jianfancloud.com/#/login website |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
将入组的患者数据统一录入EDC数据管理系统;经常自查数据记录的准确性、完整性,更正错误时要按照规定的方法;数据的统计处理采用经验证的、可靠的统计软件,数据的输入采用有效的质控措施,如双人或双次录入。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Enter the data of enrolled patients uniformly into the EDC (Electronic Data Capture) data management system; regularly self-check the accuracy and completeness of data records, and correct errors according to prescribed methods; statistical processing of data shall be performed using validated and reliable statistical software, and data entry shall employ effective quality control measures, such as double-entry or dual-person verification. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |